Press release
Equine Encephalitis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Bavarian Nordic, Merck & Co, Ridgeback Biotherapeutics, AlphaVax, Mapp Biopharmaceuti
Equine Encephalitis Clinical Trials
DelveInsight reports that over five key companies are actively developing more than five therapeutic candidates for Equine Encephalitis.
Equine Encephalitis Overview:
Western, Eastern, and Venezuelan equine encephalitis viruses vary in infection rates and severity, but all can produce flu-like symptoms, neurological complications, and in some cases, fatal outcomes. These viruses are transmitted to humans via mosquito bites, and approximately 5% of infections can progress to the rare but serious condition of encephalitis. In the United States, cases of Eastern equine encephalitis (Triple E) have been increasing, with the CDC reporting nearly 40 cases and 15 deaths in 2019, marking the largest recorded outbreak. Currently, no vaccines are approved for any of the equine encephalitis viruses.
Request for a detailed insights report on Equine Encephalitis pipeline insights [https://www.delveinsight.com/report-store/equine-encephalitis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Equine Encephalitis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Equine Encephalitis Therapeutics Market.
Key Takeaways from the Equine Encephalitis Pipeline Report
*
DelveInsight's Equine Encephalitis (EE) pipeline report highlights a dynamic landscape with over five companies developing more than five therapeutic candidates for EE.
*
Key players such as Bavarian Nordic, Merck & Co, Ridgeback Biotherapeutics, AlphaVax, Mapp Biopharmaceutical, and others are advancing new drugs to enhance treatment options for equine encephalitis.
*
Promising pipeline candidates in various stages of development include MVA-BN Registered WEV, Molnupiravir, and others.
Bavarian Nordic's MVA-BN WEV Vaccine:
*
Phase 1 Clinical Trial: The company completed a Phase 1 trial for the MVA-BN WEV vaccine, a trivalent recombinant Modified Vaccinia Ankara-based vaccine targeting Western, Eastern, and Venezuelan equine encephalitis viruses. The trial showed the vaccine was well-tolerated and immunogenic, eliciting neutralizing antibody responses against all three viruses across different dose groups.
*
Phase 2 Plans: Based on these encouraging results, Bavarian Nordic plans to initiate a Phase 2 dose-finding study in 2025 to further assess the vaccine's safety and efficacy.
Equine Encephalitis Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Equine Encephalitis Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Equine Encephalitis treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Equine Encephalitis market.
Download our free sample page report on Equine Encephalitis pipeline insights [https://www.delveinsight.com/sample-request/equine-encephalitis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Equine Encephalitis Emerging Drugs
*
MVA-BN Registered WEV: Bavarian Nordic
*
Molnupiravir: Ridgeback Biotherapeutics/Merck
Equine Encephalitis Companies
Over five leading companies are actively working on therapies for equine encephalitis, with Bavarian Nordic advancing the most progressed candidates, currently in Phase I clinical trials.
DelveInsight's report covers around 5+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Equine Encephalitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Equine Encephalitis Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Equine Encephalitis Therapies and Key Companies: Equine Encephalitis Clinical Trials and advancements [https://www.delveinsight.com/report-store/equine-encephalitis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Equine Encephalitis Pipeline Therapeutic Assessment
- Equine Encephalitis Assessment by Product Type
- Equine Encephalitis By Stage
- Equine Encephalitis Assessment by Route of Administration
- Equine Encephalitis Assessment by Molecule Type
Download Equine Encephalitis Sample report to know in detail about the Equine Encephalitis treatment market @ Equine Encephalitis Therapeutic Assessment [https://www.delveinsight.com/sample-request/equine-encephalitis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Equine Encephalitis Current Treatment Patterns
4. Equine Encephalitis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Equine Encephalitis Late-Stage Products (Phase-III)
7. Equine Encephalitis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Equine Encephalitis Discontinued Products
13. Equine Encephalitis Product Profiles
14. Equine Encephalitis Key Companies
15. Equine Encephalitis Key Products
16. Dormant and Discontinued Products
17. Equine Encephalitis Unmet Needs
18. Equine Encephalitis Future Perspectives
19. Equine Encephalitis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Equine Encephalitis Pipeline Reports Offerings [https://www.delveinsight.com/report-store/equine-encephalitis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=equine-encephalitis-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-bavarian-nordic-merck-co-ridgeback-biotherapeutics-alphavax-mapp-biopharmaceuti]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Equine Encephalitis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Bavarian Nordic, Merck & Co, Ridgeback Biotherapeutics, AlphaVax, Mapp Biopharmaceuti here
News-ID: 4160489 • Views: …
More Releases from ABNewswire
Hypothalamic Obesity Market: Epidemiology, Pipeline Therapies, and Leading Compa …
The hypothalamic obesity market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM hypothalamic obesity market size from 2020 to 2034. The report also covers current hypothalamic obesity treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.
Emerging therapies for Hypothalamic Obesity, including LB54640 and others, are anticipated to drive significant growth in the…
Lennox Gastaut Syndrome Clinical Trials, Companies, Therapeutic Assessment, Ther …
DelveInsight's, "Lennox-Gastaut Syndrome - Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lennox-Gastaut Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight reports that over 10 key companies are actively developing…
Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials, Companies, Th …
DelveInsight's, "Chronic inflammatory demyelinating polyneuropathy (CIDP)- Pipeline Insight, 2025" report provides comprehensive insights about 2+ companies and 4+ pipeline drugs in Chronic inflammatory demyelinating polyneuropathy (CIDP)pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
DelveInsight reports that more than two key companies are actively developing over four therapeutic candidates for…
Severe Asthma Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Appr …
DelveInsight's, "Severe Asthma Pipeline Insight 2025" report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Severe Asthma pipeline landscape. It covers the Severe Asthma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Severe Asthma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight's comprehensive Severe Asthma Pipeline…
More Releases for Equine
Equine Insurance Market Is Going to Boom | Major Giants Petplan Equine, Lloyd's …
HTF MI just released the Global Equine Insurance Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2032. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach.
Major Giants in Equine Insurance Market are:
Markel Corporation (USA), Great American…
Equine Veterinary Therapeutics Market Pioneering Advances and Emerging Trends Sh …
𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧:
The equine veterinary therapeutics market is an essential segment of the broader veterinary industry, driven by continuous advancements in treatments, technologies, and the increasing demand for specialized healthcare for horses. As the industry evolves, new therapeutic approaches are emerging, not only to address traditional equine health concerns but also to enhance performance, recovery, and overall well-being.
The equine veterinary therapeutics market is projected to grow from US$1.37 billion in 2023…
Peterson Smith Equine Hospital Unveils State-of-the-Art CT Wing, Enhancing Equin …
Ocala, FL - Peterson Smith Equine Hospital is pleased to formally announce its latest enhancement in equine healthcare with the inauguration of our recently completed CT Wing. This significant addition underscores our commitment to advancing diagnostic capabilities for the benefit of our patients and clients.
The project included comprehensive upgrades to our lobby and examination rooms, along with the construction of a cutting-edge standing surgery suite. The highlight of this development…
Equine Pharmaceuticals And Supplements Market
Equine Pharmaceuticals And Supplements Market: Overview
Numerous people take supplements to help prevent vitamin, mineral, and electrolyte deficiencies as well as to enhance their health and performance. The human health industry is flooded with supplements that promise to balance the diet, boost athletic performance, or alleviate health issues, and the horse supplement industry has developed significantly over the past 20 years. Owners and caregivers of horses now have access to a…
Equine Supplement Products Market Worth US$ 1,15,932.42 thousand by 2028 | Plusv …
According to our new market research study on “Equine Supplement Products Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Supplements, Application, Distribution Channel, and Geography,” the market is expected to reach US$ 1,15,932.42 Thousand in 2028 from US$ 89,436.31 Thousand in 2021. The market is estimated to grow with a CAGR of 3.8% from 2021-2028. Key factors that are driving growth of the market are benefits…
Global Equine Supplement Products Market 2020 Business Strategies – Bayer AG, …
The market report titled “Equine Supplement Products Market: by Supplement (Proteins/ Amino Acids, Vitamins, Enzymes, Electrolytes/ Minerals, and Others), by Application (Performance Enhancement, Joint Disorder Prevention, and Others), and by Distribution Channel (Veterinary Hospital Pharmacies, Retail Pharmacies, and Others): Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 – 2025” and published by Zion Market Research will put forth a systematizedevaluation of the vital facets of the global Equine Supplement Products…
